A selective, endogenous TRPV1 agonist that is a “hybrid” analog, which incorporates components of both the AEA-like and dopamine neurotransmitter pathways; binds to the human recombinant TRPV1 (Ki = 36 nM) with equipotency to that of capsaicin and slightly more potency than that of N-arachidonoyl dopamine; causes hyperalgesia and nocifensive behavior that is blocked by the TRPV1 antagonist iodo-resiniferatoxin; has weak affinity for the rat CB1 receptor (Ki = 1.6 µM) and is a very weak inhibitor of FAAH; inhibits 5-LO from rat RBL-1 cells (IC50 = 7.5 nM).